The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

BACKGROUND: ER+/HER2− breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. METHODS: A total of 1702 postmenopausal ER+/HER2− breast cancer patients from two adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubsky, P, Brase, J C, Jakesz, R, Rudas, M, Singer, C F, Greil, R, Dietze, O, Luisser, I, Klug, E, Sedivy, R, Bachner, M, Mayr, D, Schmidt, M, Gehrmann, M C, Petry, C, Weber, K E, Fisch, K, Kronenwett, R, Gnant, M, Filipits, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859949/
https://www.ncbi.nlm.nih.gov/pubmed/24157828
http://dx.doi.org/10.1038/bjc.2013.671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859949/
https://www.ncbi.nlm.nih.gov/pubmed/24157828
http://dx.doi.org/10.1038/bjc.2013.671

Ejemplares similares